Details for New Drug Application (NDA): 218002
✉ Email this page to a colleague
NDA 218002 describes TAFLUPROST, which is a drug marketed by Ingenus Pharms Llc, Micro Labs, and Sandoz, and is included in three NDAs. It is available from three suppliers. Additional details are available on the TAFLUPROST profile page.
The generic ingredient in TAFLUPROST is tafluprost. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the tafluprost profile page.
The generic ingredient in TAFLUPROST is tafluprost. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the tafluprost profile page.
Summary for 218002
| Tradename: | TAFLUPROST |
| Applicant: | Ingenus Pharms Llc |
| Ingredient: | tafluprost |
| Patents: | 0 |
Pharmacology for NDA: 218002
| Mechanism of Action | Prostaglandin Receptor Agonists |
| Physiological Effect | Increased Prostaglandin Activity |
Suppliers and Packaging for NDA: 218002
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TAFLUPROST | tafluprost | SOLUTION/DROPS;OPHTHALMIC | 218002 | ANDA | Ingenus Pharmaceuticals, LLC | 50742-339 | 50742-339-30 | 6 POUCH in 1 CARTON (50742-339-30) / 5 VIAL, SINGLE-DOSE in 1 POUCH (50742-339-05) / .3 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.0015% | ||||
| Approval Date: | Apr 5, 2024 | TE: | AT | RLD: | No | ||||
Complete Access Available with Subscription
